CD20 antigen loss post‐venetoclax/anti‐ CD20 therapy in chronic lymphocytic leukaemia: Frequency, characteristics and potential therapeutic implications
British Journal of Haematology · 16.11.2026
DOI: 10.1111/bjh.70948 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, online erschienen am 16.11.2026. Verfasst von Tamasine Stewart und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Venetoclax plus anti‐CD20 monoclonal antibody (mAb) regimens have revolutionised treatment for chronic lymphocytic leukaemia (CLL); however, CD20 antigen loss is a potential consequence. Given emerging roles for re‐treatment with venetoclax plus anti‐CD20 mAb and CD20‐targeting bispecific antibodies in CLL, we retrospectively assessed the prevalence of CD20‐negative CLL in patients treated with fixed‐duration venetoclax/obinutuzumab (Ven‐O) or venetoclax/rituximab (Ven‐R). CD20 expression was assessed by flow cytometry at baseline, end of treatment (EOT) and disease progression, with negativity defined if the log difference in median fluorescence intensity (MFI) between CLL cells and T‐cell controls was less than 0.5. Of 60 patients, (34 Ven‐O, 26 Ven‐R), 6 demonstrated pre‐therapy CD20 negativity (1 treatment‐naïve, 5 pre‐treated) and 10/29 (34%) with measurable residual disease (MRD) at EOT demonstrated post‐therapy CD20 loss (4 Ven‐O, 6 Ven‐R). Notch receptor 1 ( NOTCH1 ) variants were identified in 5/10 (50%) patients with CD20‐negative MRD, compared to 3/18 (17%) with CD20‐positive MRD and 6/29 (21%) with undetectable MRD. Five patients had longitudinal assessment, with all demonstrating persistent CD20‐negative disease long after antibody exposure (follow‐up 12–39 months). These results have potential implications for future treatment selection and efficacy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
- Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Victoria, Australia.
- Department of Haematology, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.
- Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia.
- School of Nursing and Midwifery, La Trobe University, Melbourne, Victoria, Australia.
ORCID-Profile: Tamasine Stewart, Sean McKeague, Divya Somasekharannair, Ashley Whitechurch, Joshua Casan, Neil Came, Kylie Baldwin, Ing Soo Tiong, Sean Harrop, Mary Ann Anderson, John F Seymour, Philip A Thompson, Kah Lok Chan
Zitieren
APA
Stewart, T., McKeague, S., Somasekharannair, D., Lau, L. S., Whitechurch, A., Casan, J., Came, N., Baldwin, K., Nguyen, V., Tiong, I. S., Harrop, S., Anderson, M. A., Seymour, J. F., Westerman, D., Thompson, P. A., & Chan, K. L. (2026). CD20 antigen loss post‐venetoclax/anti‐ CD20 therapy in chronic lymphocytic leukaemia: Frequency, characteristics and potential therapeutic implications. British Journal of Haematology. https://doi.org/10.1111/bjh.70948
Vancouver
Stewart T, McKeague S, Somasekharannair D, Lau LS, Whitechurch A, Casan J, et al. CD20 antigen loss post‐venetoclax/anti‐ CD20 therapy in chronic lymphocytic leukaemia: Frequency, characteristics and potential therapeutic implications. British Journal of Haematology. 2026. doi:10.1111/bjh.70948
BibTeX
@article{Stewart2026,
author = {Stewart, Tamasine and McKeague, Sean and Somasekharannair, Divya and Lau, Lei-Shong and Whitechurch, Ashley and Casan, Joshua and Came, Neil and Baldwin, Kylie and Nguyen, Vuong and Tiong, Ing Soo and Harrop, Sean and Anderson, Mary Ann and Seymour, John F and Westerman, David and Thompson, Philip A and Chan, Kah Lok},
title = {CD20 antigen loss post‐venetoclax/anti‐ CD20 therapy in chronic lymphocytic leukaemia: Frequency, characteristics and potential therapeutic implications},
journal = {British Journal of Haematology},
year = {2026},
doi = {10.1111/bjh.70948}
}
EUVIMED